| |
Mergers and acquisitions are common in clinical research, requiring flexibility and agility. When a sponsor changed mid-trial, Premier seamlessly maintained regulatory compliance, patient safety, and data integrity.
Learn how in our case study.
|
|
Today’s Big NewsNov 4, 2024 |
| By James Waldron Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist. |
|
|
|
By James Waldron Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed data from its phase 1 trial that suggest its dual agonist of GLP-1 and GIP can hold its own in a crowded field. |
By James Waldron AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space. |
Sponsored by Dell Technologies While artificial intelligence is on everyone’s minds and in many R&D plans, adoption of generative AI has been slow so far in life sciences. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies.
|
|
By Gabrielle Masson BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline. |
By Darren Incorvaia TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover antibodies for idiopathic pulmonary fibrosis. |
By Darren Incorvaia Israeli computational biology company Evogene is looking to the clouds to secure the computational power it needs to develop an AI model for designing small molecules. |
By Angus Liu As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against competitors. |
By Heather Landi The Centers for Medicare and Medicaid Services is moving forward with a 2.9% cut to physician payments in 2025 despite protest from major industry groups. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy. |
|
|---|
|
|
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
